6 Best Peptides for Cutting (Fat Loss Phase)

What to Know Before Choosing a Peptide for a Cutting Phase

The field of peptides people reach for during a fat loss phase is wider and more varied than most guides let on. At one end you have FDA-approved medications with multiple large-scale randomized controlled trials behind them. At the other end you have research compounds whose entire evidence base is community-reported experience and rodent studies. Both ends belong in an honest guide, and both are represented here.

A peptide earned a slot in this list because people use it for cutting, or are actively discussing using it for that goal. That is the whole test. Regulatory status and evidence depth shape how each compound is described, never whether it appears. Where the human trial data is strong, the entry says so and names the trials. Where the only evidence is community-reported, the entry says that plainly. A reader who already knows the landscape will recognize every compound here, and that recognition is the point.

The entries are numbered by how prominently each compound appears in research and documented real-world use, not as a recommendation of one over another. Semaglutide sits at number one because it is the most widely prescribed and most thoroughly studied of the group. MOTS-c sits at number six because it is far more speculative and far less discussed in mainstream cutting protocols. Neither position is a verdict on what you should use. Individual goals, health history, and a lot of other variables determine the right choice, and that is precisely what the MyPeptidePal app is built to work through.

One practical note before the entries: this is a "which peptide" guide, not a protocol guide. Dose numbers, injection schedules, and cycle lengths are not here. That information lives inside the app, where it can be matched to your specific situation rather than printed as generic instructions.

1. Semaglutide: For Broad, Sustained Fat Loss

Semaglutide is a GLP-1 receptor agonist, meaning it mimics glucagon-like peptide-1, a hormone your body naturally releases after eating to signal fullness and regulate blood sugar. When that signal is amplified and extended by a weekly injection, the result is a sustained reduction in appetite and a slowing of gastric emptying, which means food stays in your stomach longer and you feel full sooner and for longer. The downstream effect is a meaningful, sustained caloric deficit without the constant conscious fight against hunger that makes most diets fail.

The evidence for semaglutide in fat loss is the strongest of any compound on this list. The STEP 1 trial, a randomized controlled study of nearly 2,000 adults, found average body weight reduction of approximately 14.9 percent over 68 weeks at the highest approved dose. Some subgroup and longer-duration data have shown losses approaching 22 percent. Those are not community reports or animal model findings; they are replicated, peer-reviewed results from large-scale trials. Semaglutide is FDA-approved under the brand name Wegovy for chronic weight management in adults who meet BMI criteria, and it is widely available through telemedicine prescriptions for qualifying patients.

Real-world user accounts broadly match the trial data, with community discussion commonly describing losses of 30 to 45 pounds over three to six months in people who struggled to lose weight through diet and exercise alone. The effect users describe most often is not a dramatic fat-burning sensation; it is that food simply stops commanding attention the way it once did.

The side effect profile is worth understanding before starting. Nausea, diarrhea, constipation, and vomiting are the most commonly reported effects, and they tend to be dose-dependent, appearing most prominently during dose escalation. More serious but uncommon risks include gallbladder disease and, rarely, pancreatitis. Semaglutide carries an FDA boxed warning for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, for whom it is contraindicated. Anyone considering it should have that conversation with a prescribing physician.

2. Tirzepatide: For Maximum Fat Loss With Metabolic Benefits

Tirzepatide is the first drug to simultaneously activate both GLP-1 receptors and GIP receptors, the GIP standing for glucose-dependent insulinotropic polypeptide. The dual activation matters because each pathway contributes something different. The GLP-1 component reduces appetite and slows gastric emptying, the same mechanism semaglutide works through. The GIP component adds a layer of direct metabolic action on fat cells and enhanced insulin signaling that appears to amplify overall fat loss beyond what GLP-1 agonism alone produces.

The clinical evidence is comprehensive and compelling. The SURMOUNT-1 trial enrolled more than 2,500 non-diabetic adults over 72 weeks. At the highest dose studied, average weight loss reached approximately 20.9 percent of body weight. The lower doses produced roughly 15 to 19.5 percent. Head-to-head data comparing tirzepatide with semaglutide consistently show tirzepatide producing roughly 40 percent more total weight loss. It is FDA-approved under the brand name Zepbound for chronic weight management, and like semaglutide it is available through telemedicine for qualifying patients.

Community discussion of tirzepatide is consistently positive. Users frequently describe results that exceed their expectations from previous attempts with diet and exercise alone. A small number of tracking cases have used DEXA scanning to confirm the composition of weight lost, finding predominantly fat mass reduced alongside some lean mass. That lean mass observation is worth taking seriously: users in community protocols consistently note that resistance training and adequate protein intake are important safeguards when running any GLP-1 class agent.

The safety and contraindication profile mirrors semaglutide closely: GI side effects during escalation, the same boxed warning for thyroid carcinoma history, and the same cautions around pancreatitis and gallbladder disease. Anyone considering tirzepatide should do so under physician supervision, which is straightforward given its approved and telemedicine-available status.

3. Retatrutide: For Aggressive Cutting With Maximum Appetite Suppression

Retatrutide is the most potent fat-loss agent discussed in this guide and also the only one that is not yet FDA-approved. It is a triple receptor agonist, simultaneously activating GLP-1, GIP, and glucagon receptors. The glucagon component is what sets it apart from the compounds above. Glucagon receptor activation directly mobilizes fat through the liver and raises the basal metabolic rate in a way that neither semaglutide nor tirzepatide does. The three pathways together produce synergistic fat loss that exceeds what dual or single agonism achieves.

Phase 2 trial data showed average weight loss of approximately 24 percent at 48 weeks, with some dose cohorts approaching higher figures. That places retatrutide roughly 60 percent above semaglutide in terms of absolute weight loss and meaningfully above tirzepatide as well. Phase 3 trial results are expected in 2026. Until those results are published and an FDA approval decision is made, retatrutide is a research compound, available from research chemical channels but not through mainstream telemedicine or pharmacy.

Community use of retatrutide has grown substantially in advance of approval. User-reported outcomes describe very aggressive cuts: 35 pounds in approximately two months in some cases, with individuals reaching single-digit body fat percentages for the first time. The appetite suppression is consistently described as the most profound of any GLP-1-class compound currently accessible, with several users noting that the compound essentially removes the hunger and cravings that make cutting difficult. A case involving concurrent use with MOTS-c described 8 pounds of fat lost in 8 weeks alongside improved energy and exercise performance.

The safety profile in trials resembles the GLP-1 class: nausea, GI discomfort, and the lean mass loss risk that DEXA tracking in community self-reports has captured. Because it is not yet FDA-approved, there is no prescribing physician pathway and no standardized oversight. Users pursuing it outside a clinical setting are operating without the guardrails that physician monitoring provides, which is a meaningful practical consideration.

4. Tesamorelin: For Visceral Fat With Muscle Preservation

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, the signal your hypothalamus sends to your pituitary gland to trigger growth hormone release. It does not add exogenous growth hormone; it amplifies your body's own natural pulsatile GH production. That elevated GH then drives lipolysis, particularly in visceral adipose tissue, the deep abdominal fat that wraps around organs and is often the most stubborn and metabolically consequential fat depot to reduce.

The compound has a more specific evidence base than the GLP-1 agents. Two Phase 3 randomized controlled trials confirmed significant reductions in visceral adipose tissue measured by CT scan, and those results earned it FDA approval under the brand name Egrifta SV. The catch is that the approval is narrow: it covers reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, a condition where antiretroviral treatment disrupts fat distribution. Use for general cutting in healthy individuals is off-label. That off-label status does not make it rare in practice; functional medicine and longevity-oriented clinicians use it fairly commonly for visceral fat reduction outside the HIV context, and it shows up consistently in community cutting stacks.

What makes tesamorelin particularly valuable in a fat loss phase is that it targets visceral fat while simultaneously protecting lean muscle through the IGF-1 cascade that follows elevated GH. That anti-catabolic effect is something the GLP-1 agents do not provide on their own, which is why tesamorelin and other GH-axis peptides appear in stacks alongside appetite-suppressing compounds rather than as replacements for them. Community protocols most often pair it with ipamorelin, describing the combination as a standard approach for cutting phases that prioritize body composition rather than just the number on the scale.

Side effects include water retention and peripheral edema, joint stiffness, and possible alterations in glucose handling that warrant monitoring for anyone with blood sugar concerns. It is contraindicated in active or historical hormone-sensitive malignancy and in pregnancy. The muscle-preserving and visceral-fat-specific profile is real, but it operates on GH axis mechanics that carry more systemic downstream effects than the direct lipolytic approach of the compound below.

5. AOD-9604: For Targeted Lipolysis Without GH Effects

AOD-9604 is a synthetic fragment derived from the C-terminal end of human growth hormone, spanning amino acids 176 through 191 with a modification at the first position. The key engineering decision in its design was to isolate the region of the GH molecule responsible for stimulating fat breakdown, specifically its action on beta-3 adrenergic receptors in fat cells, while stripping out the parts responsible for systemic growth effects, IGF-1 elevation, and the glucose disruption that come with full growth hormone therapy.

The evidence picture is more complicated than most sources admit. AOD-9604 was originally developed as an anti-obesity drug and advanced to Phase 2 and Phase 3 human trials. It did not demonstrate statistically significant weight loss versus placebo at the doses tested, which is why it never received FDA approval for obesity. That is a real finding, not a technicality. The compound does not have positive Phase 3 human trial data for fat loss. It does have animal model evidence supporting the lipolytic mechanism, and it has a substantial community following, particularly among people who want a fat-loss adjunct that does not touch blood sugar or the GH axis.

Users in community protocols tend to reach for AOD-9604 in two specific contexts: late in a cutting phase when they are already lean and want to address stubborn fat deposits, and in circumstances where they cannot or prefer not to use GLP-1 agents or GH-axis compounds. The clean profile, meaning no glucose disruption and no growth-promoting side effects, is its primary practical appeal. Several community guides describe modest effects in the range of a few pounds of fat reduction over typical cycle lengths, positioning it as a finishing agent rather than a primary driver.

The honest framing for AOD-9604 is that it is a niche research compound with a rationally appealing mechanism, real but limited animal evidence, and a failure to replicate that mechanism into significant human weight loss in formal trials. It remains widely discussed in cutting communities and used anecdotally by people who report value in it, but anyone choosing it should understand they are working with a compound whose human efficacy evidence is thin.

6. MOTS-c: For Metabolic Enhancement During a Cut

MOTS-c is unusual in its origins. Unlike every other compound on this list, it is a peptide encoded not by the nuclear genome but by the mitochondrial genome, produced inside mitochondria themselves. It functions as a metabolic signaling molecule, activating AMPK, the AMP-activated protein kinase pathway that acts as the cell's primary fuel sensor. When AMPK is activated, the cell shifts toward burning stored fuel rather than storing more: fat oxidation increases, glucose uptake into muscle improves, and mitochondrial energy production becomes more efficient. Researchers studying MOTS-c have described its effects as resembling the metabolic changes produced by exercise at the cellular level.

The critical honesty point for MOTS-c is that no human clinical trial data has been published for this compound in a fat loss context as of 2026. The evidence base consists of animal studies and in vitro experiments, plus a growing collection of community-reported experiences. It is a research compound in the fullest sense: the mechanism is real and theoretically compelling, but whether that mechanism translates into meaningful fat loss in humans has not been established by controlled research.

The community use case for MOTS-c is not as a primary fat-loss driver. It appears in cutting protocols almost exclusively as an adjunct added to support energy and exercise performance during a caloric deficit, a phase when many people notice their training capacity decline. One user-reported case combined MOTS-c with retatrutide and described improved cardio performance and sustained energy alongside significant fat loss, though separating MOTS-c's contribution from retatrutide's in that kind of stack is not possible from a single anecdotal report. It is best understood as a speculative metabolic optimization layer, potentially meaningful if its mechanism translates to humans, but offering no clinical proof that it does.

How These Peptides Compare

Frequently Asked Questions

Are peptides for cutting legal to use?

It depends entirely on which compound you are asking about. Semaglutide and tirzepatide are FDA-approved prescription medications, legally available through a prescribing physician or telemedicine platform for people who meet the qualifying criteria. Tesamorelin is also FDA-approved, though for a narrow indication, and off-label use is legal under physician supervision. Retatrutide, AOD-9604, and MOTS-c are research compounds, not approved for human use in the United States, and they occupy a different legal category entirely. Anyone considering these should understand the regulatory status of the specific compound before proceeding.

How do GLP-1 peptides actually reduce hunger?

GLP-1 receptors are found in both the gut and the brain. When a GLP-1 agonist like semaglutide or tirzepatide activates them, two things happen simultaneously: gastric emptying slows down so food physically stays in your stomach longer, and appetite signaling in the hypothalamus shifts to reduce the drive to eat and the intensity of food cravings. Users frequently describe the experience as food losing its psychological pull rather than any dramatic sensation of fullness. The combined effect creates a sustained caloric deficit that does not require the same constant conscious effort as restriction-based dieting.

Do cutting peptides cause muscle loss along with fat loss?

GLP-1 class agents, including semaglutide, tirzepatide, and retatrutide, can contribute to lean mass loss alongside fat mass, particularly at aggressive dose levels or without protective countermeasures. Community tracking using DEXA scanning has found that in some cases a meaningful portion of total weight lost includes lean tissue rather than purely fat. The standard response in community protocols is to prioritize resistance training and adequate protein intake throughout the cut. Tesamorelin and other GH-axis peptides are sometimes added specifically for their anti-catabolic effect, since elevated GH stimulates IGF-1 production, which helps preserve skeletal muscle during a caloric deficit.

How long does it take to see results from cutting peptides?

The FDA-approved GLP-1 agents show measurable weight loss in most users within the first four to eight weeks of titration, with the most significant effects accumulating over six to twelve months of continued use. Research compounds like AOD-9604 and MOTS-c have no established clinical timeline because no controlled human trials have defined one; the evidence here is user-reported and individual variation is high. Tesamorelin community protocols often describe noticeable body composition changes, particularly abdominal tightening, appearing after ten to fourteen weeks of consistent use. No cutting peptide produces rapid overnight results, and the compounds with the most robust evidence are precisely the ones designed for sustained use rather than short cycles.

Do any of these peptides work without injections?

Semaglutide has an oral tablet form called Rybelsus, FDA-approved for type 2 diabetes and sometimes used off-label for weight management, though the injectable forms produce more consistent results. All other compounds on this list require subcutaneous injection because peptide bonds are broken down by digestive enzymes before the compound can reach the bloodstream in active form. The convenience gap between oral and injectable is real, and it is one reason the GLP-1 agents attract the broadest audience: for people willing to inject, the data is strong; for those seeking a non-injectable option, the choices narrow significantly.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for cutting and fat loss phases in one place.